Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of IV NEPA versus oral NEPA for prevention of chemotherapy-induced nausea and vomiting during highly emetogenic chemotherapy
2015-001800-74Phase 3Completed
- Sponsor
- Helsinn
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of netupitant and palonosetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Helsinn. Primary endpoint: Safety endpoints. Started Jun 2015; status: completed.
02
Drugs
netupitantpalonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2015-001800-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001800-74.